imiquimod

Details

Generic Name:
imiquimod
Project Status:
Withdrawn
Therapeutic Area:
Gynecological cancers
Manufacturer:
N/A
Brand Name:
N/A
Project Line:
Reimbursement Review
Project Number:
PX0364-000
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Non-sponsored Submission
Fee Schedule:
Pending
Indications:
For the treatment of high grade squamous intraepithelial lesions (HSIL) (CIN 2 and 3) of the cervix and of Paget’s disease of the vulva.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Key Milestones2
Submission receivedMarch 21, 2024
Clarification:

- Submission was voluntarily withdrawn by the sponsor on 15-Apr-2024